By Fineline Cube 
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2025 financial report for the period ended March 31, 2025. The company recorded RMB 30.598 billion (USD 4.2 billion) in revenues, marking a 13.2% year-on-year (YOY) increase. Net profit surged by 62.2% YOY to RMB 1.432 billion (USD 198.3 million), while the adjusted net profit reached RMB 1.95 billion (USD 270 million) after a 35.6% expansion.
Business Segment Performance
AliHealth’s pharmaceutical self-operated business generated RMB 26.124 billion (USD 3.62 billion) in sales, representing a 10% YOY growth. The pharmaceutical e-commerce platform business saw significant expansion with a 54% YOY increase in sales to RMB 3.588 billion (USD 497 million). However, sales of the medical health and digital service business decreased by 7.6% to RMB 885 million (USD 123 million). Tmall’s pharmaceutical platform continued to show steady Gross Merchandise Volume (GMV) growth, with Stock Keeping Units (SKUs) exceeding 133 million and self-operated SKUs reaching 1.23 million.
Innovation and Digital Services
AliHealth continued to promote the application of Medical Large Language Models (MLLMs), enhancing AI capabilities in areas such as intelligent search recommendations, intelligent supply chain management, and intelligent customer service. The company’s traditional Chinese medicine (TCM) Internet hospital, integrated with DEEPSEEK during the year, now boasts 140,000 registered TCM practitioners.
Drug Tracking Platform
The “mashangfangxin.com”, AliHealth’s drug tracking platform, has issued over 8.5 million electronic drug testing reports and served more than 8,600 enterprises. This initiative underscores the company’s commitment to advancing the digitalization of drug circulation compliance.-Fineline Info & Tech